POLI: A Drug Target for Various Diseases (G11201)

Target Name: POLI

NCBI ID: G11201

POLI

POLI: A Drug Target for Various Diseases

POLI (Proteasome-Localized Inhibitor) is a drug target (or biomarker) that is being targeted for potential therapeutic intervention in various diseases, including cancer. POLI is a protein that is expressed in various cell types and has been shown to play a role in the regulation of protein interactions and the degradation of damaged proteins, which are thought to be involved in the development and progression of many diseases.

One of the key features of POLI is its ability to localize to specific protein-protein interaction sites within cells. This is accomplished through the use of a unique conformational change that allows the protein to form a covalent complex with target proteins. Once bound, POLI can inhibit the activity of these target proteins, leading to a reduction in their levels and potentially leading to the inhibition of their functions.

POLI has been shown to be involved in the regulation of a wide range of cellular processes, including cell division, apoptosis (programmed cell death), and signaling pathways. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of targeting POLI as a drug or biomarker is its ability to specifically target proteins that are involved in disease development and progression. This is because the majority of diseases are caused by the over-expression or dysfunction of specific proteins, and targeting these proteins can potentially lead to the development of effective therapeutic approaches.

Another advantage of targeting POLI is its potential to be used in combination with other therapeutic approaches. For example, POLI has been shown to be highly cross-resistance, meaning that it is not dependent on the specificity of the target protein, which makes it a potential candidate for use in combination with other therapies that target different proteins.

While the use of POLI as a drug target or biomarker is still in its early stages, it holds great promise for the development of new therapeutic approaches for a wide range of diseases. By targeting specific proteins that are involved in disease development and progression, and by using it in combination with other therapeutic approaches, it may be possible to develop effective treatments for a variety of conditions.

Overall, POLI is a drug target (or biomarker) that is being targeted for potential therapeutic intervention in a wide range of diseases. Its ability to localize to specific protein-protein interaction sites and its potential to be used in combination with other therapeutic approaches make it a promising candidate for the development of new treatments. Further research is needed to fully understand the role of POLI in disease and to develop effective treatments.

Protein Name: DNA Polymerase Iota

Functions: Error-prone DNA polymerase specifically involved in DNA repair (PubMed:11013228, PubMed:11387224). Plays an important role in translesion synthesis, where the normal high-fidelity DNA polymerases cannot proceed and DNA synthesis stalls (PubMed:11013228, PubMed:11387224, PubMed:14630940, PubMed:15199127). Favors Hoogsteen base-pairing in the active site (PubMed:15254543). Inserts the correct base with high-fidelity opposite an adenosine template (PubMed:15254543). Exhibits low fidelity and efficiency opposite a thymidine template, where it will preferentially insert guanosine (PubMed:11013228). May play a role in hypermutation of immunoglobulin genes (PubMed:12410315). Forms a Schiff base with 5'-deoxyribose phosphate at abasic sites, but may not have lyase activity (PubMed:11251121, PubMed:14630940)

The "POLI Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLI comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets